Skip to main content
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Press Releases

<< Back
Printer Friendly Version View printer-friendly version
Seres Therapeutics to Present at Two Upcoming March Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 9, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at each of the following upcoming healthcare conferences:

  • The 38th Annual Cowen & Co. Health Care Conference: a corporate overview will be presented on Wednesday, March 14 at 10:40 a.m. ET in Boston, MA.
  • Oppenheimer's 28th Annual Healthcare Conference: a corporate overview will be presented on Tuesday, March 20 at 10:20 a.m. ET in New York, NY.

A live audio webcast of each presentation will be available under the “Investors and Media” section of Seres’ website. A replay of each presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. Seres’ clinical candidate SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate Ulcerative Colitis and has obtained Orphan Drug designation for pediatric Ulcerative Colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection and is developing SER-401 to enhance the efficacy of checkpoint inhibitors in patients with certain tumors. For more information, please visit Follow us on Twitter @SeresTx.

Source: Seres Therapeutics, Inc.

Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Vice President, Investor Relations and Corporate Communications